PARIS, France, March 15, 2022 at 6:30 p.m. (CET) – Pharnext SA (FR0011191287 – ALPHA) (“the Company”), a late-stage biopharmaceutical company, pioneering a new approach to the development of innovative drug combinations based on on genomic Big Data and artificial intelligence using its PLEOTHERAPY™ platform, drew an eighth tranche of 300 bonds convertible into shares (the “OCAs”) with a nominal value of €10,000 each, and this within the framework of the amended contract for the issue of bond issues convertible or exchangeable for new and/or existing shares (the “OCEANE-BSA”) concluded with the company Global Tech Opportunities 13 (the “Investor”) .